Plasma Fibrinogen Concentrations in Patients with Solid Tumors and Therapeutic Improvements by Combining Anticoagulants or FibrinolyticalAgents

Abstract

Many of patient’s deaths with solid tumors are caused by altered pathogenesis coagulation cascade components and processes in clinics. Therapeutic actions for inhibiting cancer coagulation complications in clinics are indispensable part of modern cancer therapies. This editorial discusses the relationship between plasma/solid tumor fibrinogen levels and mechanisms of action by anticoagulants and fibrinolytic agents. Revisit old theory with latest hypothetic and therapeutic options. Many updating clinical information between fibrinogen malformation and its specific therapy are highlighted herein.